GenVec, Inc. New (NASDAQ: GNVC) reported Q4 EPS of ($0.07), versus ($0.24) reported last year. Revenue for the quarter came in at $145 thousand, versus $1.52 million reported last year. GenVec Inc. (NASDAQ:GNVC) shares after opening at $2.50 moved to $2.75 on last trade day and at the end of the day closed at $2.66. Company price to sales ratio in past twelve months was calculated as 9.00 and price to cash ratio as 6.47. GenVec Inc. (NASDAQ:GNVC) showed a negative weekly performance of -2.92%.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, on 7 April announced the addition of Ian B. Walters, M.D., MBA., a translational oncology and immunology expert. Dr. Walters was most recently an executive at Bristol Myers Squibb (BMS) where he led oncology drug development programs, large international matrix teams, and strategic transactions. Sorrento Therapeutics Inc. (NASDAQ:SRNE) shares advanced 9.33% in last trading session and ended the day on $10.55. SRNE return on equity ratio is recorded as -112.80% and its return on assets is -92.60%. Sorrento Therapeutics Inc. (NASDAQ:SRNE) yearly performance is 148.24%.
Analysts at Citigroup Inc. raised their price target on shares of Prosensa Holding NV (NASDAQ:RNA) from $4.00 to $7.50 in a research note on Wednesday, March 5th. Prosensa Holding NV (NASDAQ:RNA) shares moved up 8.33% in last trading session and was closed at $5.07, while trading in range of $4.58 – $5.12. Prosensa Holding NV (NASDAQ:RNA) year to date (YTD) performance is 8.57%.
Akebia Therapeutics Inc. (NASDAQ:AKBA) announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease in patients who are not dependent on dialysis. AKB-6548 is designed to achieve a coordinated and natural increase in red blood cell production and iron utilization that is similar to the body’s adaptive response to hypoxia, or low oxygen levels, resulting from modest increases in altitude. Akebia Therapeutics Inc. (NASDAQ:AKBA) weekly performance is 41.18%. On last trading day company shares ended up $26.09. Akebia Therapeutics Inc. (NASDAQ:AKBA) distance from 50-day simple moving average (SMA50) is 28.14%.